Skip to Content

Sarepta Therapeutics Inc SRPT

Morningstar Rating
$131.18 −6.39 (4.64%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

SRPT is trading at a 18% discount.
Price
$137.05
Fair Value
$261.22
Uncertainty
Very High
1-Star Price
$835.62
5-Star Price
$47.18
Economic Moat
Wjcq
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SRPT is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$137.57
Day Range
$129.08138.00
52-Week Range
$55.27159.77
Bid/Ask
$130.83 / $131.36
Market Cap
$12.27 Bil
Volume/Avg
908,013 / 1.2 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
11.00
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of Sarepta's product candidates are at an early stage of development.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Mid Growth
Total Number of Employees
1,162

Comparables

Valuation

Metric
SRPT
MRNA
RARE
Price/Earnings (Normalized)
36.29
Price/Book Value
16.832.6915.77
Price/Sales
11.005.518.93
Price/Cash Flow
Price/Earnings
SRPT
MRNA
RARE

Financial Strength

Metric
SRPT
MRNA
RARE
Quick Ratio
4.633.212.32
Current Ratio
5.443.422.61
Interest Coverage
−30.09−113.82−8.62
Quick Ratio
SRPT
MRNA
RARE

Profitability

Metric
SRPT
MRNA
RARE
Return on Assets (Normalized)
−6.45%−20.12%−33.88%
Return on Equity (Normalized)
−33.09%−26.85%−233.97%
Return on Invested Capital (Normalized)
−11.50%−26.68%−182.73%
Return on Assets
SRPT
MRNA
RARE
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRRmxw$541.4 Bil
VRTX
Vertex Pharmaceuticals IncQcmdnt$110.3 Bil
REGN
Regeneron Pharmaceuticals IncKjwkqf$108.4 Bil
MRNA
Moderna IncPdpn$37.2 Bil
ARGX
argenx SE ADRXprkp$23.7 Bil
BNTX
BioNTech SE ADRYtry$21.7 Bil
ALNY
Alnylam Pharmaceuticals IncNkmvps$19.6 Bil
BMRN
Biomarin Pharmaceutical IncDftdzr$16.7 Bil
RPRX
Royalty Pharma PLC Class AMlzcfl$13.7 Bil
INCY
Incyte CorpBzkvjv$13.5 Bil

Sponsor Center